Loading clinical trials...
Loading clinical trials...
A Double-masked Study of DE-111 Ophthalmic Solution Versus Timolol Ophthalmic Solution 0.5% in Patients With Primary Open Angle Glaucoma or Ocular Hypertension - Phase 3, Confirmatory Study -
Conditions
Interventions
DE-111 ophthalmic solution
Timolol ophthalmic solution 0.5%
+1 more
Locations
1
Japan
Santen study sites
Osaka, Osaka, Japan
Start Date
May 1, 2011
Primary Completion Date
September 1, 2012
Last Updated
July 10, 2015
NCT07396441
NCT07390890
NCT05902871
NCT07218796
NCT07119580
NCT06865144
Lead Sponsor
Santen Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions